<?xml version="1.0" encoding="UTF-8"?>
<p id="p0025">We performed a phase 1/2 open-label multicenter dose-escalation trial in 12 adult participants to evaluate the safety and tolerability of subretinal transplantation of hESC-derived RPE cells. The intervention was unmasked. The study received the approval of the Medicines and Health Products Regulatory Authority, the United Kingdom Gene Therapy Advisory Committee, and the Moorfields Eye Hospital Research Governance Committee. We provided potential candidates with detailed information, including an explanation of the aims of the trial and the possible consequences of participation. Participants provided their written informed consent before enrolment. We performed the study in accordance with the tenets of the Declaration of Helsinki and registered the trial at 
 <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov" id="intref0025" xmlns:xlink="http://www.w3.org/1999/xlink">clinicaltrials.gov</ext-link> (identifier, 
 <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT01469832" id="intref0030" xmlns:xlink="http://www.w3.org/1999/xlink">NCT01469832</ext-link>).
</p>
